Capitalizing leadership acumen
for life science innovations

MERCHANT PORTFOLIO COMPANIES

Allele Capital Partners is pleased to have invested and partnered with the following companies in their quest to bring important new medicines and medical devices to patients in need.

     
  Gain Therapeutics  
   

Praesidia Biotherapeutics

Developing a novel linker technology platform designed for organ and tissue specific delivery of drug payloads.

Praesidia is developing proprietary linkers that can be conjugated to several drug classes and targeted to diseased tissue, including across the blood-brain-barrier. For certain constructs, the linker, itself, is the targeting moiety, forgoing the need for an antibody or other ligand. The company’s lead two programs are targeting inflammation of the lungs and brain, with follow-on indications targeting cancers of the prostate and brain.

     
  Gain Therapeutics  
   

Coya Therapeutics

Regulatory T cell (Treg) and exosome platforms targeting neurodegenerative and autoimmune diseases.

Coya is a platform cellular therapy company that has developed a transformative, proprietary and scalable approach to transform millions of dysfunctional Tregs to billions of highly functional Tregs, as well as exosomes, targeting multiple diseases including Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia and scleroderma.​

     
  Gain Therapeutics  
   

Gain Therapeutics

Leading the discovery of novel allosteric binding sites through computational chemistry and artificial intelligence (AI) to create new medicines.

Gain is unlocking new treatment options for difficult-to-treat disorders characterized by protein misfolding, including lysosomal storage disorders. Protein misfolding is an underlying biological issue of many diseases, including lysosomal storage disorders and neurodegenerative diseases such as Parkinson’s disease.​

     
  Gain Therapeutics  
   

INVO Bioscience

A medical device company focused on creating simplified, lower cost treatments for patients diagnosed with infertility.

The INVO® Procedure is a revolutionary in vivo method of vaginal incubation that offers patients a more natural and intimate experience. INVOcell® is a patented medical device to treat infertility and is considered an Assisted Reproductive Technology (ART). It is the world’s first Intravaginal Culture (IVC) system for natural in vivo incubation of eggs and sperm during fertilization and early embryo development, an alternative to traditional IVF and IUI.

     
  Gain Therapeutics  
   

NeuBase Therapeutics

A revolutionary antisense oligonucleotide (ASO) platform technology that tackles genetic disease at its root cause with scalpel-like precision.

NeuBase is developing an entirely new class of post-precision medicine with remarkable characteristics and near limitless scalability: ultra-precision. The proprietary PATrOL™ platform can shape the function of genes with a novel exactness and individualized approach that has the potential to increase treatment options and reduce suffering for hundreds of millions of people impacted by genetic diseases.

     
  Gain Therapeutics  
   

ZyVersa Therapeutics

Targeting inflammasomes and cholesterol mediation for patients with high unmet medical needs.

ZyVersa is developing IC 100, a novel monoclonal antibody that inhibits a component of the inflammasome (adaptor ASC) to block initiation and perpetuation of the inflammatory cascade. The company is also developing VAR 200, a cholesterol efflux mediator that removes excess cholesterol from the kidney's filtration system to protect against structural damage, reduce proteinuria, and preserve function.